VEGF、Hsa-miR-93、S100A8在乳腺癌中的表达及与预后的关系分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1781 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the expressions of vascular endothelial growth factor (VEGF), Hsa-miR-93, and S100 calcium binding protein A8 (S100A8) in breast cancer and their relationship with prognosis. Methods The cancer tissues and corresponding para-carcinoma nomal tissues were collected from 77 patients pathologically confirmed with new breast cancer who were treated in the Chizhou People’s Hospital from January 2017 to June 2018. The expressions of VEGF and S100A8 in tissues were detected by immunohistochemistry; the expression of Hsa-miR-93 was detected by in situ hybridization method; the relationship between VEGF, Hsa-miR-93, S100A8 levels and clinicopathological characteristics of patients were analyzed; according to patients’ survival data of three years after surgery, the effects of VEGF, HSA-miR-93, and S100A8 expression levels on prognosis and survival were analyzed. Results The positive expression rates of VEGF, Hsa-miR-93, and S100A8 in breast cancer tissues were higher than those in para-carcinoma nomal tissues (P < 0.05). The positive expression of VEGF in cancer tissues was related to lymph node metastasis (P < 0.05), while not related to age, histological grading, TNM staging or tumor diameter (P > 0.05); the positive expression of Hsa-miR-93 in cancer tissues was related to TNM staging and lymph node metastasis (P < 0.05), while not related to age, histological grading or tumor diameter (P > 0.05); the positive expression of S100A8 in cancer tissues was related to histological grading, TNM staging, and lymph node metastasis (P < 0.05), while not related to age or tumor diameter (P > 0.05). There was no significant difference in survival rate between patients with positive expression of VEGF, HSA-miR-93, and S100A8 in breast cancer tissues and patients with negative expression (P > 0.05). Conclusion VEGF, miR-93, and S100A8 are highly expressed in breast cancer tissues, but there is no significant difference in positive expression rate and survival rate.

Key words： Breast cancer Vascular endothelial growth factor Hsa-miR-93 S100 calcium binding protein A8 Pathological characteristic Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Liang1 WANG Dujuan2 HUANG Shubin1 XIE Qian1 LI Songmei1

Cite this article:

XU Liang1 WANG Dujuan2 HUANG Shubin1 XIE Qian1 LI Songmei1. Expressions of VEGF, Hsa-miR-93, and S100A8 in breast cancer and their relationship with prognosis[J]. 中国医药导报, 2022, 19(17): 32-36.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I17/32

[1] Lent AB，Mohan P，Derksen D，et al. The association between breast cancer capacity and resources with incidence and mortality in Arizona’s low populous counties [J]. Rural Remote Health，2021，21（3）：6357-6369.
[2] 姜涵译，张雪鹏.早期三阴性乳腺癌治疗的研究进展[J].中国医刊，2021，56（8）：830-832.
[3] Shabani F，Farasat A，Mahdavi M，et al. Calprotectin （S100A8/S100A9）：a key protein between inflammation and cancer [J]. Inflamm Res，2018，67（10）：801-812.
[4] Zhang S，Wang Z，Liu W，et al. Distinct prognostic values of S100 mRNA expression in breast cancer [J]. Sci Rep，2017，7（1）：39786-39794.
[5] 高小卓，张辉，乔鋆，等.MicroRNA-93及Tspan1在结肠癌中的表达及其临床病理意义[J].中国现代医学杂志，2020，30（21）：6-11.
[6] 张佳敏，周晓燕，郝华.脂质介质在肿瘤血管生成中的作用[J].临床与实验病理学杂志，2019，35（9）：1076-1078， 1081.
[7] Kong D，Zhou H，Neelakantan D，et al. VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk [J]. Oncogene，2021， 40（5）：964-979.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2015版）[J].中国癌症杂志，2015，25（9）：692-754.
[9] Axiotis CA，Monteagudo C，Merino MJ，et al. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma [J]. Am J Pathol，1991，138（4）：799-806.
[10] 董乐，范敏，蒲玉翠，等.社区女性乳腺癌筛查认知体验的质性研究[J].中国当代医药，2022，29（2）：149-152.
[11] Kolak A，Kamińska M，Sygit K，et al. Primary and secondary prevention of breast cancer [J]. Ann Agric Environ Med，2017，24（4）：549-553.
[12] Apte RS，Chen DS，Ferrara N. VEGF in Signaling and Disease：Beyond Discovery and Development [J]. Cell，2019，176（6）：1248-1264.
[13] Siveen KS，Prabhu K，Krishnankutty R，et al. Vascular Endothelial Growth Factor（VEGF）Signaling in Tumour Vascularization：Potential and Challenges [J]. Curr Vasc Pharmacol，2017，15（4）：339-351.
[14] 刘岩岩，童创，梁惠，等.Ki67、HER-2、VEGF和EGFR蛋白在乳腺癌组织中的表达及临床意义[J].新疆医科大学学报，2019，42（11）：1419-1422，1429.
[15] Rupaimoole R，Slack FJ. MicroRNA therapeutics：towards a new era for the management of cancer and other diseases [J]. Nat Rev Drug Discov，2017，16（3）：203-222.
[16] Liu DK，Wei YJ，Guo Y，et al. MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2 [J]. Eur Rev Med Pharmacol Sci，2018，22（8）：2343-2350.
[17] 杨正勤，王小玉，李睿，等.血清miR-93在子宫内膜癌中的表达及临床意义[J].中国计划生育和妇产科，2020， 12（1）：73-77.
[18] 刘琴，杨陈武，刘小燕，等.S100A8对大鼠肺泡巨噬细胞炎性因子释放水平的影响[J].川北医学院学报，2021， 36（10）：1271-1274.
[19] Wen H，Ma H，Cai Q，et al. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma [J]. Nat Med，2018，24（2）：154-164.
[20] 王润青，王永祥，张钲.S100A8和S100A9在冠心病中的研究进展[J].中国动脉硬化杂志，2021，29（7）：641-644.
[21] 陈宇，田华，王德权，等.S100A8、E-cadherin在膀胱癌中的表达及意义[J].中国医刊，2017，52（6）：84-86.
[22] 吕彦天，阮婷，徐国鹏.S100A8在非小细胞肺癌中的表达及其临床意义[J].临床肺科杂志，2017，22（7）：1201-1204.
[23] 于筱舟，张洪典，李小凤，等.细胞核受体酪氨酸激酶研究进展[J].癌症，2021，40（6）：243-249.
[24] Huang W，Yang Y，Wu J，et al. Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling [J]. Cell Death Differ，2020，27（5）：1709-1727.
[25] El-Sheikh Ali H，Boakari YL，Loux SC，et al. Transcriptomic analysis reveals the key regulators and molecular mechanisms underlying myometrial activation during equine placentitis [J]. Biol Reprod，2020，102（6）：1306-1325.